Literature DB >> 24072855

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.

Bruno Paiva1, Teresa Paino, Jose-Maria Sayagues, Mercedes Garayoa, Laura San-Segundo, Montserrat Martín, Ines Mota, María-Luz Sanchez, Paloma Bárcena, Irene Aires-Mejia, Luis Corchete, Cristina Jimenez, Ramon Garcia-Sanz, Norma C Gutierrez, Enrique M Ocio, Maria-Victoria Mateos, Maria-Belen Vidriales, Alberto Orfao, Jesús F San Miguel.   

Abstract

Circulating myeloma tumor cells (CTCs) as defined by the presence of peripheral blood (PB) clonal plasma cells (PCs) are a powerful prognostic marker in multiple myeloma (MM). However, the biological features of CTCs and their pathophysiological role in MM remains unexplored. Here, we investigate the phenotypic, cytogenetic, and functional characteristics as well as the circadian distribution of CTCs vs paired bone marrow (BM) clonal PCs from MM patients. Our results show that CTCs typically represent a unique subpopulation of all BM clonal PCs, characterized by downregulation (P < .05) of integrins (CD11a/CD11c/CD29/CD49d/CD49e), adhesion (CD33/CD56/CD117/CD138), and activation molecules (CD28/CD38/CD81). Fluorescence in situ hybridization analysis of fluorescence-activated cell sorter-sorted CTCs also unraveled different cytogenetic profiles vs paired BM clonal PCs. Moreover, CTCs were mostly quiescent and associated with higher clonogenic potential when cocultured with BM stromal cells. Most interestingly, CTCs showed a circadian distribution which fluctuates in a similar pattern to that of CD34(+) cells, and opposite to stromal cell-derived factor 1 plasma levels and corresponding surface expression of CXC chemokine receptor 4 on clonal PCs, suggesting that in MM, CTCs may egress to PB to colonize/metastasize other sites in the BM during the patients' resting period.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072855     DOI: 10.1182/blood-2013-06-510453

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma.

Authors:  Kosei Matsue; Hiroki Kobayashi; Yuya Matsue; Yoshiaki Abe; Kentaro Narita; Akihiro Kitadate; Masami Takeuchi
Journal:  Blood Adv       Date:  2018-05-08

2.  Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.

Authors:  Yoshiaki Abe; Kentaro Narita; Hiroki Kobayashi; Akihiro Kitadate; Daisuke Miura; Masami Takeuchi; Eri O'uchi; Toshihiro O'uchi; Kosei Matsue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

Review 3.  Tracking myeloma tumor DNA in peripheral blood.

Authors:  Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-14       Impact factor: 3.020

Review 4.  The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Authors:  Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt
Journal:  Oncologist       Date:  2016-02-26

5.  Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion.

Authors:  Sophie Laget; Lucile Broncy; Katia Hormigos; Dalia M Dhingra; Fatima BenMohamed; Thierry Capiod; Magne Osteras; Laurent Farinelli; Stephen Jackson; Patrizia Paterlini-Bréchot
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 6.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2016-07-13       Impact factor: 2.490

7.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

Authors:  W I Gonsalves; S V Rajkumar; V Gupta; W G Morice; M M Timm; P P Singh; A Dispenzieri; F K Buadi; M Q Lacy; P Kapoor; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

Review 8.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

9.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

10.  Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

Authors:  Joyce W Kamande; Maria A M Lindell; Małgorzata A Witek; Peter M Voorhees; Steven A Soper
Journal:  Integr Biol (Camb)       Date:  2018-02-19       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.